Health Care M&A Deals, May 22, 2020

Health Care M&A Deals, May 22, 2020

The Health Care M&A deals chart is a selection of transactions announced during the prior week(s). The M&A transactions presented here are from our Deal Search Online database, which is updated daily to provide our subscribers with the most up-to-date information and trends in the healthcare industry. This week’s top deals include Omada Health’s acquisitions of Physera, Inc. for $37 million and Induction Healthcare Group PLC ‘s purchase of Zesty $15.56 million. To subscribe to our Health Care M&A deals chart and more, visit our membership site. HealthCareMandA.com is devoted to healthcare merger and acquisition data for the... Read More »
Health Care M&A Deals, May 22, 2020

Health Care M&A Deals, May 15, 2020

The Health Care M&A deals chart is a selection of transactions announced during the prior week(s). The M&A transactions presented here are from our Deal Search Online database, which is updated daily to provide our subscribers with the most up-to-date information and trends in the healthcare industry. This week’s top deals include Primary Health Properties acquisition of a portfolio of medical office buildings for $66.6 million and The DNA Company’s purchase of My Pain Sensei for $30 million. To subscribe to our Health Care M&A deals chart and more, visit our membership site. HealthCareMandA.com is devoted to healthcare merger and... Read More »
April Healthcare M&A Took a Hit

April Healthcare M&A Took a Hit

Correlation doesn’t prove causation, but the evidence is hard to ignore. April healthcare M&A took a hit as COVID-19 forced businesses to close, workers to stay home, and providers to divert all their attention toward treating the flood of infected patients. Compared with last March, April saw a 21% drop in activity and a 34% drop compared with April 2019. The decline was even more pronounced among the sectors. Long-Term Care, an unfortunately hard-hit industry from the pandemic, suffered a profound drop of 40%. Our colleagues on the senior care side used the word “anemic” to describe the second half of April for Long-Term Care transactions. Half of the month’s deals closed in the... Read More »
Health Care M&A Deals, May 22, 2020

Health Care M&A Deals, May 8, 2020

The Health Care M&A deals chart is a selection of transactions announced during the prior week(s). The M&A transactions presented here are from our Deal Search Online database, which is updated daily to provide our subscribers with the most up-to-date information and trends in the healthcare industry. This week’s top deals include Portola Pharmaceuticals, Inc.’s acquisition of Alexion Pharmaceuticals, Inc. for $1.6 billion and Menarini Group’s purchase of Stemline Therapeutics Inc. for $629.7 million. To subscribe to our Health Care M&A deals chart and more, visit our membership site. HealthCareMandA.com is devoted to... Read More »
Health Care M&A Deals, May 22, 2020

Health Care M&A Deals, May 1, 2020

The Health Care M&A deals chart is a selection of transactions announced during the prior week(s). The M&A transactions presented here are from our Deal Search Online database, which is updated daily to provide our subscribers with the most up-to-date information and trends in the healthcare industry. This week’s top deals include Molina Healthcare, Inc.’s acquisition of Magellan Complete Care for $850 million, Supernus Pharmaceuticals, Inc.’s purchase of a CNS drug portfolio for $300 million, and AMEDISYS, INC.’s acquisition with AsceraCare Hospice for $203 million. To subscribe to our Health Care M&A deals chart and more, visit our membership... Read More »
Health Care M&A Deals, May 22, 2020

Health Care M&A Deals, April 24, 2020

The Health Care M&A deals chart is a selection of transactions announced during the prior week(s). The M&A transactions presented here are from our Deal Search Online database, which is updated daily to provide our subscribers with the most up-to-date information and trends in the healthcare industry. This week’s top deals include Takeda Pharmaceutical Co. Ltd. ‘s divesture of its European product portfolio for $575 million and Otsuka Pharmaceutical Co., Ltd. license agreement for Nexletol and Nexlizet in Japan with Esperion Therapeutics Inc. for $60 million. To subscribe to our Health Care M&A deals chart and more, visit our membership site. HealthCareMandA.com is... Read More »